Concord Biotech reported a 12% drop in FY26 revenue to ₹1,055 crore and a 30% decline in profit to ₹259 crore, citing external challenges. Despite this, the company maintained a strong EBITDA margin and commissioned a new injectable facility.
Concord Biotech Reports FY26 Financials Amidst External Challenges
Revenue from operations for FY26 stood at ₹1,054.89 crore, a decrease from ₹1,200.09 crore in the previous year. Profit for the year was ₹259.22 crore, down from ₹371.65 crore in FY25. Reader Takeaway: Revenue and profit decline due to external factors, but strong margins and new facility offer future growth. ## What just happened Concord Biotech reported its full-year financial results for FY26, showing a decline in both revenue and profit compared to FY25. Consolidated revenue fell by 12% to ₹1,054.89 crore, and profit for the year decreased by 30% to ₹259.22 crore. ## Why this matters The decline impacts shareholder returns in the short term. However, the company highlighted that the challenges were primarily external and timing-related. The robust EBITDA margin of 34.8% and strategic investments, including a new injectable facility, indicate potential for recovery and future growth. ## The backstory In FY21, Concord Biotech had higher customer concentration, with the top 10 customers accounting for 48.2% of revenue. This has since been reduced to approximately 37.6% in FY26, showing improved risk management. ## What changes now The Valthera injectable facility was commissioned in FY25 and received WHO GMP certification in FY26. It has a peak revenue potential of ₹600 crore and is expected to contribute significantly from FY27. Concord also expanded into the Cell & Gene Therapy space. ## Risks to watch Management cited macro-economic headwinds such as US tariff uncertainty, geopolitical disruptions, and customer procurement delays as reasons for the FY26 performance. Sustained pricing pressure in the generics market is also a watch point. ## Peer comparison No direct peer comparison data is available in the filing. ## Context metrics (time-bound) Consolidated Revenue for FY26: ₹1,054.89 Crore. Profit for the Year FY26: ₹259.22 Crore. EBITDA Margin FY26: 34.8%. Dividend announced: ₹7.55 per share. ## What to track next Investors will be closely monitoring the ramp-up of the new injectable facility and the normalization of customer procurement cycles in the upcoming fiscal year.
